Chemically treated plasma Aβ is a potential blood-based biomarker for screening cerebral amyloid deposition

Table 3 Detailed information of ROC curve analysis

Panel	AUC	Sensitivity (%)	Specificity (%)	P value	Cutoff criterion	95% CI of AUC
ND– vs ND+
MPP-Aβ42/40	0.639	71.8	51.5	<0.0001	>0.1871	0.559–0.719
MPP-Aβ42/40 + age + gender	0.695	79.0	57.8	<0.0001	>0.1864	0.622–0.767
MPP-Aβ42/40 + age + gender + ApoE	0.783	80.7	69.2	<0.0001	>0.1730	0.715–0.852
PiB– vs PiB+
MPP-Aβ42/40	0.668	71.0	52.2	<0.0001	>0.2731	0.605–0.731
MPP-Aβ42/40 + age + gender	0.682	71.0	54.2	<0.0001	>0.2759	0.622–0.741
MPP-Aβ42/40 + age + gender + ApoE	0.799	78.0	66.8	<0.0001	>0.2230	0.746–0.852

ApoE Apolipoprotein E, AUC area under curve, MPP mixture of protease inhibitors and phosphatase inhibitors, CI confidence interval, ROC receiver operating characteristic, – or + PiB-PET positivity, ND– PiB-PET-negative cognitively normal (CN) and PiB-PET-negative subjects with mild cognitive impairment (MCI), ND+ PiB-PET-positive CN and PiB-PET-positive MCI, PiB– grouped CN–, MCI–, and ADD–, PiB+ grouped CN+, MCI+, and ADD+

ISSN: 1758-9193